Respiratory Flashcards

1
Q

Metabolic acidosis causes

Changes to ABG

A

Increased H+ production e.g. DKA
Decreased H+ excretion e.g. renal tubular acidosis; renal failure
Bicarbonate loss e.g. intestinal fistula

ABG changes
If uncompensated:
- High H+
- Low bicarbonate

If compensated:

  • High H+
  • Low bicarbonate
  • Low CO2 (can’t compensate if resp failure - H+ will rise more)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Respiratory acidosis
Causes

Changes to ABG

A

Poor ventilation
Poor perfusion
Impaired gas exchange

If chronic

  • COPD
  • Emphysema

ABG changes
If uncompensated:
- High CO2; high H+; high HCO3-

If compensated:
High CO2; normalised H+; high HCO3-; PH may be normal now

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Metabolic alkalosis causes

A
  • Hypokalaemia
  • H+ loss e.g. pyloric stenosis, vomiting
  • Ingestion of bicarbonate (tx for GI ulcer)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Causes of respiratory alkalosis

A

Hyperventilation

  • Anxiety
  • Hypoglycaemia

Salicyclate poisoning
CNS disorders: stroke, subarachnoid haemorrhage, encephalitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Aspirin overdose picture on ABG

A

Mixed metabolic acidosis and respiratory alkalosis
Hyperventilation stimulated
Hydrogen excretion by kidney

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Define chronic bronchitis
- symptoms

Complications

Pathology

A

chronic cough productive of sputum for at least 3 months over at least 2 consecutive years

Symptoms
Repeated infections
Resp failure, reduced exercise tolerance
Increased lung cancer risk (independent of smoking)

Complications
Chronic hypoxia results in PULMONARY HTN AND RHF
= aka cor-pulmonale
- Peripheral oedema
- Hepatosplenomegaly
- Raised JVP

Pathology

  • Dilation of the airways
  • Mucus gland hyperplasia
  • Goblet cell hyperplasia
  • Mild inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Bronchiectasis define

Causes

Complications

A

Permanent dilation of the bronchi with scarring

Causes

  1. Inflammatory
    - post infection
    - immunodeficiency (hypogammoglbulinaeia) or secondary
    - obstruction
    - post inflammatory (aspiration)
    - Secondary to bronchiolar disease and interstitial fibrosis
    - systemic disease
    - Asthma
  2. Congenital
    - CF
    - primary ciliary dyskinesia
    - hypogammaglobulinemia
    - yellow nail syndrome
    - young’s syndrome (Rhinosinusitis, Azoospermia, Bronchiectasis)

Complications

  • Recurrent infections
  • Haemoptysis
  • Pulmonary HTN
  • Amyloidosis (as producing excessive amyloid A protein)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What does honeycomb lung indicate?

Categories

A

Interstitial Lung disease
- all have at end stage

Categories

1) Fibrosis
2) Granulomatous
3) Eosinophilic
4) Smoking related

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is a saddle embolus?

What does it lead to

A

Large pulmonary thrombo-embolism that straddles the main pulmonary arterial trunk at its bifurcation

Leads to

  • Acute cor pulmonale
  • Cardiogenic shock
  • Death If >60% of pulmonary bed occluded

NB - wedge infarct = Pulmonary infarction (commonly after PE), Repeated infarctions can cause pulmonar HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is alpha-1 antitrypsin deficiency

Clinical picture

Management

A

Common inherited condition caused by a lack of a protease inhibitor (Pi) normally produced by the liver. The role of A1AT is to protect cells from enzymes such as neutrophil elastase.

Clinical picture

lungs: panacinar emphysema, most marked in lower lobes
liver: cirrhosis and hepatocellular carcinoma in adults, cholestasis in children

Management

  • no smoking
  • supportive: bronchodilators, physiotherapy
  • intravenous alpha1-antitrypsin protein concentrates
  • surgery: volume reduction surgery, lung transplantation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

COPD prophylaxis example

What needs monitoring

A

Azithromycin prophylaxis
- patients should not smoke, have optimised standard treatments and continue to have exacerbations
other prerequisites include a CT thorax (to exclude bronchiectasis) and sputum culture (to exclude atypical infections and tuberculosis)

Ned to do
LFTs and an ECG to exclude QT prolongation should also be done as azithromycin can prolong the QT interval

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Obstructive sleep apnoea

Consequences

A

Consequences

  • HTN
  • Day time somnolence
  • Compensated respiratory acidosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ARDS definition

Diagnosis

Causes

A

Non cardiogenic pulmonary oedema ((i.e. the pulmonary capillary wedge pressure must not be raised) and diffuse pulmonary infiltrates, refractory hypoxaemia, stiff lungs and respiratory distress. ARDS forms part of a systemic inflammatory reaction.

Diagnosis = 3 criteria

1) Acute onset (within 1 week)
2) Bilateral opacities on CXR
3. ) PaO2 /FiO2 (arterial to inspired oxygen) ratio of less than/= 300 on PEEP (positive end-expiratory pressure) or CPAP more than/equal 5cm H20

Causes

  • Pulmonary: Trauma, shock, infection, gas inhalation, aspiration, mechanical ventilation
  • Systemic: Shock/sepsis, pancreatitis, burns, cardiopulmonary bypass, DIC, Oxygen toxicity, drug overdose, ops (eclampsia)
Clinical presentation
• Tachypnoea, often unexplained
• Dyspnoea
• Cyanosis
• Peripheral vasodilation
• Bilateral fine inspiratory crackles on auscultation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ARDS investigations

Management

Prognosis

A

•Sputum/Urine cultures:
•Blood tests: FBC, U&Es, LFTs, Amylase, Clotting screen, Blood cultures, BNP
•ABG
•CXR: Bilateral infiltrates
•Pulmonary artery catheter: Measure pulmonary capillary wedge pressure + demonstrate arterial hypoxaemia, refractory to oxygen therapy
o = 18 suggests ARDS but not done routinely

Management
Treat underlying cause whilst giving supportive measures
- PEEP
- Non-ventilatory management: NO/Prostacyclin
- Steroids
- Circulatory support (as in pulmonary oedema)
- Antimicrobials (if infectious cause)

Prognosis

  • Mortality is 30-50%: Death most often due to multiple organ failure
  • Pts who survive usually have residual decrease in lung function
  • Muscle weakness, neuropathies, joint disorders and chronic pain common in survivors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Respiratory failure type 1

Causes

Clinical presentation

Management

A

PaO2 <8kPa. PaCO2 is normal or low

V/Q mismatch

Causes
•	Severe acute asthma
•	Pneumonia
•	PE
•	Pulmonary oedema
Clinical presentation
•	Dyspnoea
•	Restless and agitated
•	Confusion
•	Cyanosis (peripheral and central)

Management

  • High flow O2
  • Consider CPAP if O2 remains <8kPa despite 60% O2
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Type 2 respiratory failure

Causes

Clinical presentation

Management

A

Low PaO2 <8kPa;
High PaO2 > 6.5kPa

Known as ventilatory failure; the rise in PaCO2 is no longer matched by an increase in ventilation.

Causes
- most common cause is (COPD). Others include chest-wall deformities, respiratory muscle weakness (e.g. Guillain-Barre syndrome) and central depression of the respiratory centre (e.g. heroin overdose)

Clinical presentation:

  • As in type 1: Dyspnoea, restless, confusion, cyanosis
  • Headache
  • Drowsiness
  • Confusion
  • Tachycardia with a bounding pulse
  • Tremor in hands
  • Peripheral vasodilation
  • Papilloedema

Management
•Use O2 therapy conservatively: start at 24% via facemask
•Recheck PaCO2 after 20 mins (ABG)
•If PaCO2 is stable, oxygen can be increased. If it has risen, consider alternative support i.e. non invasive positive pressure ventilation such as biphasic positive airway pressure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

PE definition

Pathophysiology

A

Obstruction of one or more pulmonary arteries, mostly embolism is caused by blood thrombi, which arise from deep vein system in legs or pelvis (DVT)

Pathophysiology
Thrombus formation –> DVT in leg or pelvis –> embolisation to pulmonary arteries via IVC –> partial or complete pulmonary arteries

Response of lung to arterial obstruction

  • Infarction and inflammation: Causes pleuritic chest pain and haemoptysis
  • Impaired gas exchange: V/Q mismatch
  • Cardiac compromise
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

PE aetiology

RIsk factors

Presentation

A

Aetiology

  • DVT
  • Fat embolism
  • Others
Risk factors (SPASMODICAL)
•Sex: F
•Pregnancy (+ other hypercoagulable states): Caesarean, pre-eclampsia
•Age: 
•Surgery: classically 10s post-op straining at stool. Major abdo/pelvic, orthopaedic
•Malignancy
•Oestrogen: OCP/HRT
•DVT/PE previous hx
•Immobility
•Colossal size
•Antiphospholipid Abs
•Lupus Anti-coagulant

Presentation

  • Dyspnoea
  • Sudden onset pleuritic pain
  • Haemoptysis
  • Syncope

Signs: Fever, Cyanosis, Tachycardia, Tachypnoea

  • RHF ( hypotension, high JVP, RV heave)
  • Evidence of DVT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

PE Well’s score factors

Action to take

Investigations

A

3: Signs/symptoms of DVT
3: PE most likely dx
1. 5: Tachycardia >100
1. 5: Immobility/surgery in 4wks
1. 5 Prior DVT/PE
1: Haemoptysis
1: Active malignancy (trt w/in 6months)

PE unlikely 0-4 points - D-dimer
PE likely > 4 points - immediate CTPA

ECG:

  • large S wave in lead I, a large Q wave in lead III and an inverted T wave in lead III - ‘S1Q3T3’
  • New RBB and RAD may occur

D-dimer

  • Generated as a result of fibrinolysis
  • -ve –> PE v unlikey
  • CTPA = gold standard
  • CXR: usually normal. May show wedge shaped opacities
  • Lower limb US
  • ABG: Arterial hypoxaemia and hypocapnia in early stages
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

PE management

A

Supportive
- Oxygen, analgesia, anticoagulation and thrombolysis if necessary

Once confirmed
1. LMWH or fondaparinux. Warfarin within 24h of diagnosis.
•Continue warfarin for at least 3 months - assess the risks and benefits of extending
•Extending warfarin beyond 3 months for patients with unprovoked PE, 6-12 months for the second and lifelong anticoagulation for further events
•For patients with active cancer use LMWH for 6 months

  1. Thrombolysis
    - 1st line treatment for massive PE where there is haemodynamic instability (e.g. hypotensive): Alteplase 10mg IV over 1 min, then 90mg IV over 2h
  2. Further measures
    - Inferior vena cava filter: in recurrent DVTs despite anticoagulation or if CI
    - DVT prophylaxis: Subcut heparin or LMWH for all immbile pts, compression stockings
21
Q

Pneumothorax definition

Pathophysiology

Aetiology

A

Accumulation of air in the pleural space in between the lung (visceral pleura) and the chest wall (parietal pleura) that can lead to partial or complete pulmonary collapse – spontaneously or following trauma

Pathophysiology
- Normally, alveolar pressure > intrapleural pressure + intrapleural pressure < atmospheric pressure
•If a communication develops between an alveolus and the pleural space, or between the atmosphere and the pleural space, gasses will follow the pressure gradient and flow into the pleural space

Aetiology

  1. Primary: Rupture of pleural bleb (congenital defect of alveolar wall connective tissue). Its typically tall, thin young
  2. Secondary: Pulmonary TB, CF, Pneumocystitis pneumonia, COPD, Other
  3. Traumatic: Blunt or penetrating
  4. Iatrogenic: Mechanical ventilation, thoracentesis, central venous catheter placement or bronchoscopy
22
Q

Pneumothorax

Clinical presentation

A

Symptoms

  • Acute onset unilateral pleuritic chest pain
  • Increasing SOB/ Sudden deterioration in existing lung condition

Signs O/E of affected side
•Reduced chest expansion
•Hyperresonance
•Reduced, absent breath sounds on auscultation
•May feel ‘bubbles’ and ‘crackles’ under skin of torso and neck if there is subcutaneous emphysem

Investigations

  • CXR: Area of increased radiolucency without lung markings, Edge of lung fields may be visible
  • CT chest: May be required to differentiate pneumothorax from bullous disease and useful in looking for evidence of underlying lung disease
  • ABG: May demonstrate hypoxia but is unlikely to alter management. Main use is when administering oxygen to pts with pneumothorax secondary to COPD
23
Q

Pneumothorax management

A
  1. Determine if primary or secondary

Primary

  • Depth < 2cm - usually discharge with follow up 2-4 weeks
  • Depth >2cm and/or breathless - Aspirate (16-18g cannula)
  • -> residual depth <2cm and improved - discharge with follow up 2-4 weeks
  • -> residual depth >2cm and not improved - Admit + Chest drain

Secondary

  • Depth <1cm - Admit. High flow O2 (unless CI). Observe 24h
  • Depth 1-2cm - Aspirate (16-18g cannula)
  • -> residual depth <1cm - Admit. High flow O2 (unless CI). Observe 24h
  • -> residual depth >1cm - Admit + chest drain
  • Depth >2cm or breathless - Admit. Chest drain

Aspirate: 2nd ICS mid-clavicular space
Chest drain in safe triangle

24
Q

Tension pneumothorax
Definition

Causes

Clinical presentation

Management

A

Air escapes into pleural space and rise above atmospheric pressure causes compression of both lungs and mediastinum  inhibits venous return to the heart –> hypotension and potentially cardiac arrest

Causes
• Positive pressure ventilation
• Stab wound or rib fracture

Clinical presentation
•Acute respiratory distress, agitation, hypotension, raised JVP
• Mediastinum pushed over into contralateral hemithorax, creating tracheal deviation
• Hyperresonance and absence of breath sounds

Management
•Do not wait for CXR if diagnosis is clinically certain
•Immediately: large bore cannula inserted into 2nd ICS in mid clavicular line, on the side of the pneumothorax + high flow O2
• Hiss of escaping air confirms diagnosis
• Aspirate until patient is less distressed, and then insert chest drain in safe triangle, leaving cannula in place until finished and the underwater seal is bubbling satisfactorily

25
Q

Cor pulmonale
Definition

Pathophysiology

A

Changes in the cardiovascular system resulting from the chronic hypoxia (and usually hypercapnia) of chronic lung disease, mainly PHT and fluid retention.

Results from following sequence:

  • Lung disease causes hypoxia, cyanosis, and sometimes polycythaemia
  • Hypoxia is sensed both within the kidney and via the carotid body, generating increases in sympathetic activity and renal vasoconstriction
  • Increased sympathetic activity (and other mechanisms) leads to renal retention of salt and water
  • This extra salt and water is mainly held in the capacitance vessels (the large veins), often with a raised JVP
  • If vascular permeability rises (particularly when the PaCO2 rises, producing peripheral vasodilatation and an increase in capillary pressure), extra fluid accumulates in dependent tissues, mainly the ankles
  • A raised JVP and ankle oedema in this setting are NOT due to impaired RV function, but to fluid overload and increased vascular permeability.
26
Q

Cor pulmonale

Clinical features

Investigations

A

Clinical features

  • The underlying disease causing the hypoxia, e.g. COPD/bronchiectasis
  • Easily visible veins and a raised JVP
  • Cyanosis and a suffused conjunctiva (polycythaemia and vessel dilatation from the raised CO2)
  • Sometimes marked polycythaemia, very rare consequences
  • Peripheral vasodilatation, with a ‘bounding’ pulse and warm peripheries
  • Ankle swelling and pitting oedema
  • RV hypertrophy (sternal heave uncommon, masked by hyperinflated lung between heart and chest wall; more often seen with the higher pressures of IPAH
  • Tricuspid incompetence (not usually severe)

Investigations
- CXR—enlarged pulmonary arteries/underlying lung disease
- FBC—may have polycythaemia
- Oximetry—cor pulmonale is unlikely if awake SaO2 >92%
- Blood gases—cor pulmonale progressively more likely as PaO2 drops below 8kPa (equivalent SaO2 ≈ 91%) and PaCO2 rises above 6kPa
- ECG—may indicate right axis deviation (RAD), p pulmonale (right atrial hypertrophy), and right bundle branch block (RBBB)
- Echo—dilated or hypertrophied RV, tricuspid regurgitation (TR), providing estimate of PAP, and exclude other diagnoses such as a patent ASD
• Overnight oximetry—to reveal unexpected degrees of hypoxia, e.g. from OSA, obesity, neuromuscular disease.

27
Q

Types of respiratory tract infections

Causes of respiratory tract infections

A

URTI

  • Sinusitis
  • Tonsilitis

LRTI

  • Bronchitis
  • Pneumonia
  • Empyema
  • Bronchiectasis
  • Lung abscess

Causes:

  • Poor swallow (CVA, muscle weakness, alcohol)
  • Abnormal ciliary function (smoking, viral infection, Kartagener’s)
  • Abnormal mucus (CF)
  • Dilated airways: bronchiectasis
  • Defects in host immunity (HIV, Immunosuppression)
28
Q

CAP causes

A

Typical

  1. Streptococcus pneumonia (30-50% of CAP
    - Gram +ve diplococci; alpha haemolysis; bile solubility
    - OVeR PS: Optochin Viridans Resistant, Pneumococci sensitive
    - Acute onset - severe, fever, rigours, lobar consolidation
    - Almost always penicillin sensitive
    - Urine antigen test available for severe CAP
  2. Haemophilus Influenzae (15-35% of CAP)
    - gram -ve cocco-bacilli; beta lactamase producing; choc agar
    - Associated with COPD
  3. Moraxella cattarrhalis
    - gram -ve coccus
    - associated with smoking
  4. S.aureus
    - gram +ve cocci (clusters)
    - ?cavitation
    - associated with recent viral infection - i.e. flu
  5. Klebsiella pneumonia
    - gram -ve rod
    - elderly; alcohol
    - haemopytsis +/- cavitation

Atypical

  1. Legionella pneumophilia
    - Choc agar
    - Aerosol spread
    - Dx = antigens in urine, antibody in serum
    - Associations: Diarrhoea, confusion, abdo pain (hepatitis), lymphopenia, hyponatraemia
    - Rx: Macrolides
  2. Coxiella Burnetti (Q-fever - animal exposure)
    - Flu like illness –> hepatitis, pneumoniyis
    - Rx: Doxycycline
  3. Chlamydia psitacci
    - Bird exposure
    - Associations: Splenomegaly, rash, haemolytic anaemia
    - Rx: Macrolides
  4. Mycoplasma (epidemics every 4 yrs)
    - Systemic symptoms
    - Joint pain; eruythma multiforme
    - Cold agglutination test - AIHA, SJS risk
29
Q

Pneumonia definition

presentation

A

Inflammation of lung alveoli

Fever
Cough
SOB
Pleuritic chest pain
Tachycardia/pnoea
Often localising signs - dullness to percussion; crackles
abnormal CXR

CAP or HAP

30
Q

HAP definition

Causative organisms

Management

A

> 48h into hospital stay. Commonly gram -ve
Need BAL

1st line: Ciprofloxacin + Vancomycin
ITU/2nd line: Piptizobactam + Vancomycin
Pseudomonas: Tazocin OR Ciprofloxacin + Gentamicin

31
Q

Types of aspergillum lung disease

A
  1. Allergic bronchopulmonary aspergillosis
    - Chronic wheeze, eosiniphillia
    - Bronchiectasis
    - Recurrent pneumonia
  2. Aspergilloma
    - Fungal ball often in pre-existing cavity
    - May cause haemoptysis
    - -> Infection, infarction, malignancy
  3. Invasive aspergillosis
    - Immunocompromised
    - Rx: Amphotericin B
32
Q

Pneumonia severity assessment and outcome

CAP treatment

A
Confusion
Urea >7
RR>/= 30
BP <90 S or 60 d
65 or over

0-1 home rx
2 hospita; rx
3 or more severe - ?ITU

Mild: Orla amoxicillin
Mod: Oral/IV Amoxicillin + Clarithromycin
Severe: IV Co-amoxiclav + Clarithromycin

33
Q

Pneumonia complications

A

LUNG

  • T1 resp failure
  • Pleural effusion
  • Empyema (pus in pleural space)
  • Lung abscess

HEART

  • AF
  • Pericarditis, Myocarditis

?Other

  • Sepsis
  • Hypotension
  • Cholestatic jaundice
  • Brain abscess
34
Q

COPD

Pathology

Symptoms

Signs

Scale for clinical assessment

A

Pathology

1) Chronic bronchitis: cough and sputum most days for 3 months of 2 consecutive years
2) Emphsema (histological diagnosis) = dilation of air spaces distal to terminal bronchioles with destruction of the alveoli

Symptoms
•	Dyspnoea
•	Chronic cough, may be productive
•	Decreased exercise tolerance
•	Wheeze
•	Weight loss and peripheral muscle weakness/wasting may occur
Signs
•	Central cyanosis
•	Tachypnoea
•       Expiratory time >5s, with pursed lip
•	Hyperexpanded/barrel 
•	Accessory muscle use
•	Intercostal indrawing 
•	 ?basal crepitations
•	Signs of cor pulmonale and CO2 retention (ankle oedema, raised JVP, warm peripheries, plethoric conjunctivae, bounding pulse, polycythaemia. Flapping tremor if CO2 acutely raised)

On palpation
• Tachycardia
• Tracheal tug
• Reduced expansion

On percussion
• Hyper resonant lung fields

On auscultation
• Quiet breath sounds (esp. in lung apices)  wheeze
• Possible basal crepitation
• Quiet heart sounds (due to overlying inflated lungs)

MRC dyspnoea scale (1-5)

  1. Not troubled by breathlessness except on strenuous exercise
  2. SOB when hurrying or walking up a slight hill
  3. Walks slower than contemporaries on level ground because of breathlessness or has to stop for breath when walking at own pace
  4. Stops for breath after walking about 100m or after a few mins on level ground
  5. Too breathless to leave the house, or breathless when dressing or undressing
35
Q

COPD investigations

Severity

COPD management

A
Spirometry: gold standard
o	FEV1/FVC of <0.7 confirms persistent airflow limitation and thus COPD
Mild: FEV1>80%
Mod: FEV1 50-79%
Sev: 30-49%
V sev: <30%

Other tests – helpful but not essential for diagnosis
• Pulse oximetry
• CXR: Classically hyperinflated lung fields, with flattened hemidiaphragms
• FBC
• Sputum culture (identify persistent organisms)
• Alpha-1-antitrypsin level (consider in young pts)
• ECG/Echo: may be useful in end-stage COPD with features of cor-pulmonale

Management
Conservative
- Stop smoking
- Yearly influenza, 5-yearly pneumococcal
- Improve nutrition/ activity

Pulmonary rehab
- Essential outpatient team - strategies to help cope with SOB

Medication

1) SABA (salbutamol) or SAMA (ipratropium) for symptoms
2) Add a LABA (salmeterol) + LAMA (tioptropium)
3) Change LABA to combined LABA + ICS ( seretide)

If asthmatic features:

2) Is LABA + ICS
3) LABA + LAM +ICS

  • any previous, secure diagnosis of asthma or of atopy
  • a higher blood eosinophil count - note that NICE recommend a full blood count for all patients as part of the work-up
  • substantial variation in FEV1 over time (at least 400 ml)
  • substantial diurnal variation in peak expiratory flow (at least 20%)

Oral medications
• Theophylline
• Carbocisteine (mucolytic)
• Rescue pack antibiotics

LTOT (end stage) considerin
- Non smokers
- PaO2 <7.3 when stable
- PaO2 7.3-8 with one of:
1_ Polycythaemia
2) Nocturnal hypoxaemia (<90%)
3) Peripheral oedema
4) Pulmonary HTN
36
Q

Asthma stepwise management

A

1) Regular preventer = Low-dose ICS
2) Initial add on inhaled LABA to low dose ICS (fixed dose or MART)
3) Consider increasing ICS to medium dose or Adding LTRA. If no response to LABA consider stopping LABA
4) Specialist therapies

NB: SABA as required from before step 1 (unless using MART)
Step up If using 3 doses a week or more

37
Q

Lung cancer mets from where?

What tests should be done if cannon-ball mets seen on CXR

A
breast cancer
colorectal cancer
renal cell cancer - most common
bladder cancer
prostate cancer

CT abdomen
PSA

38
Q

Tension pneumothorax size of cannula

A

14G

39
Q

Kartageners syndrome findings

A

Pathogenesis
dynein arm defect results in immotile cilia

Features
dextrocardia or complete situs inversus
bronchiectasis
recurrent sinusitis
subfertility (secondary to diminished sperm motility and defective ciliary action in the fallopian tubes)

Normally, the left testicle hangs lower than the right. However, patients with Kartageners syndrome it is reversed. This is due to the patient having situs inversus. Cystic fibrosis can also present similarly if they were not diagnosed at a young age. However, they would have other symptoms such as diabetes, diarrhoea and fat-soluble vitamin deficiencies. Although some antibiotics may impair sperm function and motility, there is nothing in the history to suggest he is currently taking them

40
Q

Mesothelioma

Features

A
Features
Dyspnoea, weight loss, chest wall pain
Clubbing
30% present as painless pleural effusion
Only 20% have pre-existing asbestosis
History of asbestos exposure in 85-90%, latent period of 30-40 years

Basics
Malignancy of mesothelial cells of pleura
Metastases to contralateral lung and peritoneum
Right lung affected more often than left

Investigation/diagnosis
CXR: either a pleural effusion or pleural thickening
the next step is normally a pleural CT
if a pleural effusion is present fluid should be sent for MC&S, biochemistry and cytology (but cytology is only helpful in 20-30% of cases)
Local anaesthetic thoracoscopy is increasingly used to investigate cytology negative exudative effusions as it has a high diagnostic yield (around 95%) = BEST
If an area of pleural nodularity is seen on CT then an image-guided pleural biopsy may be used

Management
Symptomatic
Industrial compensation
Chemotherapy, Surgery if operable
Prognosis poor, median survival 12 month
41
Q

Features that suggest COPD would be steroid responsive

A

Eosinophillia on bloods
Previous diagnosis of asthma or atopy
FEV1 varies over time (at least 400ml)
Substantial diurnal variation in PEF (20%)

42
Q

Small cell lung cancer

Features

Management

A

Features
usually central
arise from APUD* cells
associated with ectopic ADH, ACTH secretion
ADH → hyponatraemia
ACTH → Cushing’s syndrome
ACTH secretion can cause bilateral adrenal hyperplasia, the high levels of cortisol can lead to hypokalaemic alkalosis
Lambert-Eaton syndrome: antibodies to voltage gated calcium channels causing myasthenic like syndrome

Management
U sually metastatic disease by time of diagnosis
patients with very early stage disease (T1-2a, N0, M0) are now considered for surgery. NICE support this approach in their 2011 guidelines
However, most patients with limited disease receive a combination of chemotherapy and radiotherapy
patients with more extensive disease are offered palliative chemotherapy

43
Q

Lung cancer referral

A

Refer people using a suspected cancer pathway referral (for an appointment within 2 weeks) for lung cancer if they:
have chest x-ray findings that suggest lung cancer
are aged 40 and over with unexplained haemoptysis

Offer an urgent chest x-ray (to be performed within 2 weeks) to assess for lung cancer in people aged 40 and over if they have 2 or more of the following unexplained symptoms, or if they have ever smoked and have 1 or more of the following unexplained symptoms:
cough
fatigue
shortness of breath
chest pain
weight loss
appetite loss

Consider an urgent chest x-ray (to be performed within 2 weeks) to assess for lung cancer in people aged 40 and over with any of the following:
persistent or recurrent chest infection
finger clubbing
supraclavicular lymphadenopathy or persistent cervical lymphadenopathy
chest signs consistent with lung cancer
thrombocytosis

44
Q

Indications for steroids in sarcoidosis

A

Eye, heart or neuro involvement
Hypercalcaemia
CXR stage 2 or 3 who are symptomatic

45
Q

Asthma diagnosis in adults

A

Clinical diagnosis but can be supported by any of:
An exhaled FeNO of 40 parts per billion or greater
A post-bronchodilator improvement in lung volume of 200 ml
A post-bronchodilator improvement in FEV1 of 12% or more
A peak expiratory flow rate variability of 20% or more
An FEV1/FVC ratio <70% (it is an obstructive lung disease)

46
Q

Anaphylaxis management (with doses for >12yo and adult)

A
  • Resuscitation with intravenous (IV) fluids and oxygen.
  • Intramuscular (IM) adrenaline 0.5 mL of 1:1000.
  • Chlorphenamine (an antihistamine) 10 mg IM or slow IV infusion.
  • Hydrocortisone 200 mg IM or slow IV infusion.
47
Q

Drugs that can cause lung fibrosis

A
Amiodarone
Methotrexate, Sulfasalazine
Cytotoxic's: busulphan, bleomycin
Nitrofurantoin
Ergot-derived dopamine receptor agonists (bromocriptine, cabergoline, pergolide)
48
Q

Rifampicin

Isoniazid

Pyrazinamide

Ethambutanol

A
Rifampicin
mechanism of action: inhibits bacterial DNA dependent RNA polymerase preventing transcription of DNA into mRNA
- Potent liver enzyme inducer
- Hepatitis
- Orange secretions
- fFu-like symptoms
Isoniazid
MOA inhibits mycolic acid synthesis
- Peripheral neuropathy: prevent with pyridoxine (Vitamin B6)
- Hepatitis
- Agranulocytosis
- Liver enzyme inhibitor

MOA: converted by pyrazinamidase into pyrazinoic acid which in turn inhibits fatty acid synthase (FAS) I

  • Hyperuricaemia causing gout
  • Arthralgia, myalgia
  • Hepatitis

Ethambutol
MOA: inhibits the enzyme arabinosyl transferase which polymerizes arabinose into arabinan
- Optic neuritis: check visual acuity before and during treatment
-Dose needs adjusting in patients with renal impairment